Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| BIIB | Biogen Inc. | 0.67% | 345.22 | 1.2% | $624.02m | |
| GILD | Gilead Sciences, Inc. | -3.53% | 72.92 | 0.9% | $510.71m | |
| CELG | Celgene Corporation | 0.24% | 90.37 | 1.2% | $496.41m | |
| AMGN | Amgen Inc. | 0.50% | 197.42 | 1.2% | $485.34m | |
| ILMN | Illumina, Inc. | -0.34% | 325.88 | 3.5% | $373.70m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 0.67% | 374.26 | 2.6% | $315.78m | |
| VRTX | Vertex Pharmaceuticals Incorporated | 0.64% | 176.08 | 1.9% | $209.08m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -1.09% | 116.00 | 2.0% | $186.59m | |
| A | Agilent Technologies, Inc. | -1.28% | 64.66 | 1.5% | $159.27m | |
| SRPT | Sarepta Therapeutics, Inc. | 0.52% | 130.25 | 16.6% | $142.46m | |
| NKTR | Nektar Therapeutics | 0.13% | 60.03 | 5.6% | $126.29m | |
| BLUE | Bluebird Bio, Inc. | 1.15% | 158.00 | 14.6% | $121.57m | |
| EXAS | Exact Sciences Corporation | 0.33% | 48.84 | 25.3% | $118.82m | |
| BMRN | BioMarin Pharmaceutical Inc. | 0.69% | 101.01 | 4.4% | $118.74m | |
| INCY | Incyte Corporation | 1.40% | 68.80 | 2.5% | $111.73m |
Company Profile
Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micrometastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded on April 11, 2011 and is headquartered in Madison, WI.